

Michael Kassiou

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5580598/publications.pdf>

Version: 2024-02-01

295
papers

10,951
citations

30070
54
h-index

45317
90
g-index

314
all docs

314
docs citations

314
times ranked

11891
citing authors

#	ARTICLE	IF	CITATIONS
1	Measuring Affinity of Ligands to the Oxytocin Using. Methods in Molecular Biology, 2022, 2384, 231-245.	0.9	0
2	TSPO PET Imaging as a Biomarker of Neuroinflammation in Neurodegenerative Disorders. Neuromethods, 2022, , 407-427.	0.3	2
3	Pharmacological characterization of a structural hybrid P2X7R antagonist using ATP and LL-37. European Journal of Pharmacology, 2022, 914, 174667.	3.5	5
4	Biomarker discovery and development for frontotemporal dementia and amyotrophic lateral sclerosis. Brain, 2022, 145, 1598-1609.	7.6	17
5	Purinergic P2X ₇ Receptor: A Therapeutic Target in Amyotrophic Lateral Sclerosis. ACS Chemical Neuroscience, 2022, 13, 1479-1490.	3.5	5
6	Differential mitochondrial protein interaction profile between human translocator protein and its A147T polymorphism variant. PLoS ONE, 2022, 17, e0254296.	2.5	1
7	Novel plasma protein binding analysis method for a PET tracer and its radiometabolites: A case study with [¹¹ C]SMW139 to explain the high uptake of radiometabolites in mouse brain. Journal of Pharmaceutical and Biomedical Analysis, 2022, 219, 114860.	2.8	3
8	Strategies for targeting the P2Y ₁₂ receptor in the central nervous system. Bioorganic and Medicinal Chemistry Letters, 2022, 71, 128837.	2.2	3
9	Development and clinical translation of P2X ₇ receptor antagonists: A potential therapeutic target in coronary artery disease?. , 2022, 237, 108228.		9
10	The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist. European Journal of Medicinal Chemistry, 2021, 210, 113087.	5.5	6
11	Synthesis and antitumour evaluation of indole-2-carboxamides against paediatric brain cancer cells. RSC Medicinal Chemistry, 2021, 12, 1910-1925.	3.9	1
12	Cannabis and Cannabinoids. Australian Journal of Chemistry, 2021, 74, 367.	0.9	1
13	DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells. International Journal of Molecular Sciences, 2021, 22, 4011.	4.1	12
14	Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells. Cell Death Discovery, 2021, 7, 81.	4.7	31
15	Modulation of human T-type calcium channels by synthetic cannabinoid receptor agonists in vitro. Neuropharmacology, 2021, 187, 108478.	4.1	16
16	A binge high sucrose diet provokes systemic and cerebral inflammation in rats without inducing obesity. Scientific Reports, 2021, 11, 11252.	3.3	21
17	Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line. European Journal of Pharmacology, 2021, 902, 174098.	3.5	2
18	Prodromal neuroinflammatory, cholinergic and metabolite dysfunction detected by PET and MRS in the TgF344-AD transgenic rat model of AD: a collaborative multi-modal study. Theranostics, 2021, 11, 6644-6667.	10.0	42

#	ARTICLE	IF	CITATIONS
19	Adventures in Translocation: Studies of the Translocator Protein (TSPO) 18 kDa*. Australian Journal of Chemistry, 2021, , .	0.9	1
20	Senolytics: A Novel Strategy for Neuroprotection in ALS?. International Journal of Molecular Sciences, 2021, 22, 12078.	4.1	9
21	The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 379-389.	6.4	44
22	Insight into the Structural Features of TSPO: Implications for Drug Development. Trends in Pharmacological Sciences, 2020, 41, 110-122.	8.7	20
23	O-GlcNAcylation of truncated NAC segment alters peptide-dependent effects on α -synuclein aggregation. Bioorganic Chemistry, 2020, 94, 103389.	4.1	10
24	Targeting the MAPK7/MMP9 axis for metastasis in primary bone cancer. Oncogene, 2020, 39, 5553-5569.	5.9	20
25	Altered serum protein levels in frontotemporal dementia and amyotrophic lateral sclerosis indicate calcium and immunity dysregulation. Scientific Reports, 2020, 10, 13741.	3.3	26
26	Tricyclic heterocycles display diverse sensitivity to the A147T TSPO polymorphism. European Journal of Medicinal Chemistry, 2020, 207, 112725.	5.5	4
27	PET imaging of P2X7R in the experimental autoimmune encephalomyelitis model of multiple sclerosis using [11C]SMW139. Journal of Neuroinflammation, 2020, 17, 300.	7.2	15
28	Rapid Antibacterial Activity of Cannabichromenic Acid against Methicillin-Resistant Staphylococcus aureus. Antibiotics, 2020, 9, 523.	3.7	12
29	Onset of hippocampal network aberration and memory deficits in P301S tau mice are associated with an early gene signature. Brain, 2020, 143, 1889-1904.	7.6	12
30	The novel P2X7 receptor antagonist PKT100 improves cardiac function and survival in pulmonary hypertension by direct targeting of the right ventricle. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 319, H183-H191.	3.2	15
31	Anaesthetic-dependent changes in gene expression following acute and chronic exposure in the rodent brain. Scientific Reports, 2020, 10, 9366.	3.3	23
32	Reversing binding sensitivity to A147T translocator protein. RSC Medicinal Chemistry, 2020, 11, 511-517.	3.9	4
33	Novel Furan-2-yl-1 <i>H</i> -pyrazoles Possess Inhibitory Activity against α -Synuclein Aggregation. ACS Chemical Neuroscience, 2020, 11, 2303-2315.	3.5	9
34	Evaluation of ¹⁸ F-IAM6067 as a sigma-1 receptor PET tracer for neurodegeneration <i>in vivo</i> in rodents and in human tissue. Theranostics, 2020, 10, 7938-7955.	10.0	7
35	Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists. Pharmacology Research and Perspectives, 2020, 8, e00566.	2.4	16
36	Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Science Signaling, 2020, 13, .	3.6	219

#	ARTICLE	IF	CITATIONS
37	Cubanes in Medicinal Chemistry. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 1078-1095.	6.4	97
38	An overview of late-stage functionalization in today's drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2019, 14, 1137-1149.	5.0	140
39	In vitro determination of the efficacy of illicit synthetic cannabinoids at CB ₁ receptors. <i>British Journal of Pharmacology</i> , 2019, 176, 4653-4665.	5.4	46
40	First Nondiscriminating Translocator Protein Ligands Produced from a Carbazole Scaffold. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8235-8248.	6.4	13
41	CNS cell type-specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation. <i>Journal of Biological Chemistry</i> , 2019, 294, 14149-14162.	3.4	10
42	Synthesis and evaluation of various heteroaromatic benzamides as analogues of α -ylidene-benzamide cannabinoid type 2 receptor agonists. <i>Tetrahedron Letters</i> , 2019, 60, 151019.	1.4	7
43	Neuroinflammation in frontotemporal dementia. <i>Nature Reviews Neurology</i> , 2019, 15, 540-555.	10.1	159
44	Strategies to develop selective CB2 receptor agonists from indole carboxamide synthetic cannabinoids. <i>European Journal of Medicinal Chemistry</i> , 2019, 180, 291-309.	5.5	19
45	Recent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders. <i>International Journal of Molecular Sciences</i> , 2019, 20, 3161.	4.1	173
46	Synthesis of Usnic Acid Derivatives and Evaluation of Their Antiproliferative Activity against Cancer Cells. <i>Journal of Natural Products</i> , 2019, 82, 1768-1778.	3.0	27
47	Imaging disease activity of rheumatoid arthritis by macrophage targeting using second generation translocator protein positron emission tomography tracers. <i>PLoS ONE</i> , 2019, 14, e0222844.	2.5	17
48	Challenges and Opportunities in Central Nervous System Drug Discovery. <i>Trends in Chemistry</i> , 2019, 1, 612-624.	8.5	46
49	Synthesis and in vitro evaluation of fluorine-18 benzimidazole sulfones as CB2 PET-radioligands. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 5086-5098.	2.8	13
50	α -GlcNAc Modification Protects against Protein Misfolding and Aggregation in Neurodegenerative Disease. <i>ACS Chemical Neuroscience</i> , 2019, 10, 2209-2221.	3.5	56
51	Radiosynthesis of (<i>R,S</i>)- ^{18}F CE387: A Potential PET Radiotracer for Imaging Translocator Protein 18 kDa (TSPO) with Low Binding Sensitivity to the Human Gene Polymorphism rs6971. <i>ChemMedChem</i> , 2019, 14, 982-993.	3.2	22
52	New-generation azaindole-adamantyl-derived synthetic cannabinoids. <i>Forensic Toxicology</i> , 2019, 37, 350-365.	2.4	11
53	Structure-metabolism relationships of valine and tert-leucine-derived synthetic cannabinoid receptor agonists: a systematic comparison of the in vitro phase I metabolism using pooled human liver microsomes and high-resolution mass spectrometry. <i>Forensic Toxicology</i> , 2019, 37, 316-329.	2.4	24
54	Hydroxamic Acid Inhibitors Provide Cross-Species Inhibition of <i>Plasmodium</i> M1 and M17 Amino peptidases. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 622-640.	6.4	30

#	ARTICLE	IF	CITATIONS
55	Targeting the Oxytocin System: New Pharmacotherapeutic Approaches. Trends in Pharmacological Sciences, 2019, 40, 22-37.	8.7	43
56	In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids. FASEB Journal, 2019, 33, lb384.	0.5	0
57	Multi-modal imaging of long-term recovery post-stroke by positron emission tomography and matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Communications in Mass Spectrometry, 2018, 32, 721-729.	1.5	15
58	The chemistry and pharmacology of synthetic cannabinoid SDB-006 and its regioisomeric fluorinated and methoxylated analogs. Drug Testing and Analysis, 2018, 10, 1099-1109.	2.6	12
59	The evolving science of phytocannabinoids. Nature Reviews Chemistry, 2018, 2, .	30.2	55
60	Identification of the allosteric P2X7 receptor antagonist [11C]SMW139 as a PET tracer of microglial activation. Scientific Reports, 2018, 8, 6580.	3.3	54
61	Translational evaluation of translocator protein as a marker of neuroinflammation in schizophrenia. Molecular Psychiatry, 2018, 23, 323-334.	7.9	159
62	Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in "legal high" products and human urine samples. Drug Testing and Analysis, 2018, 10, 196-205.	2.6	78
63	Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration. Molecular Imaging and Biology, 2018, 20, 94-102.	2.6	88
64	The role of polycyclic frameworks in modulating P2X7 receptor function. Tetrahedron, 2018, 74, 1207-1219.	1.9	7
65	Conformationally rigid derivatives of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin-1a receptors. European Journal of Medicinal Chemistry, 2018, 143, 1644-1656.	5.5	6
66	Longitudinal investigation of neuroinflammation and metabolite profiles in the <sc>APP</sc>_{swe}-<sc>PS</sc>1_Pe9</sub> transgenic mouse model of Alzheimer's disease. Journal of Neurochemistry, 2018, 144, 318-335.	3.9	26
67	In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F]DPA714 PET. Journal of Neuroinflammation, 2018, 15, 314.	7.2	64
68	Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET. Journal of Neuroinflammation, 2018, 15, 346.	7.2	46
69	Remarkable Enhancement in Boron Uptake Within Glioblastoma Cells With Carboranyl-Indole Carboxamides. Chemistry - an Asian Journal, 2018, 13, 3321-3327.	3.3	5
70	Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A. Bioorganic and Medicinal Chemistry, 2018, 26, 5852-5869.	3.0	5
71	Peptides, Peptidomimetics, and Carbohydrate-Peptide Conjugates as Amyloidogenic Aggregation Inhibitors for Alzheimer's Disease. ACS Chemical Neuroscience, 2018, 9, 1530-1551.	3.5	70
72	Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors. Pharmacological Research, 2018, 134, 166-178.	7.1	8

#	ARTICLE	IF	CITATIONS
73	Flexible Analogues of Azaindole DYRK1A Inhibitors Elicit Cytotoxicity in Glioblastoma Cells. Australian Journal of Chemistry, 2018, 71, 789.	0.9	6
74	IL-1b release and pore formation induced by the human antimicrobial peptide LL-37 may be P2Y13 receptor-mediated. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-41.	0.0	0
75	Pharmacological exploration of peptide ligands with short residence-time at the oxytocin receptor. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-74.	0.0	0
76	Pyrazolo[1, 4]diazepine-based small molecule oxytocin receptor partial agonists. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-1-24.	0.0	0
77	The Polyphenol Altenusin Inhibits in Vitro Fibrillization of Tau and Reduces Induced Tau Pathology in Primary Neurons. ACS Chemical Neuroscience, 2017, 8, 743-751.	3.5	32
78	Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. Neuroscience and Biobehavioral Reviews, 2017, 74, 126-138.	6.1	23
79	Acute and residual effects in adolescent rats resulting from exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. Journal of Psychopharmacology, 2017, 31, 757-769.	4.0	21
80	Structural Optimization and Pharmacological Evaluation of Inhibitors Targeting Dual-Specificity Tyrosine Phosphorylation-Regulated Kinases (DYRK) and CDC-like kinases (CLK) in Glioblastoma. Journal of Medicinal Chemistry, 2017, 60, 2052-2070.	6.4	41
81	Kinase targets in CNS drug discovery. Future Medicinal Chemistry, 2017, 9, 303-314.	2.3	24
82	Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists. European Journal of Medicinal Chemistry, 2017, 130, 433-439.	5.5	24
83	Ring-opened aminothienopyridazines as novel tau aggregation inhibitors. MedChemComm, 2017, 8, 1275-1282.	3.4	7
84	Investigation of pyrazolo-sulfonamides as putative small molecule oxytocin receptor agonists. European Journal of Medicinal Chemistry, 2017, 136, 330-333.	5.5	4
85	Imaging of Glial Cell Activation and White Matter Integrity in Brains of Active and Recently Retired National Football League Players. JAMA Neurology, 2017, 74, 67.	9.0	134
86	Synthesis and Pharmacological Profiling of the Metabolites of Synthetic Cannabinoid Drugs APICA, STS-135, ADB-PINACA, and 5F-ADB-PINACA. ACS Chemical Neuroscience, 2017, 8, 1673-1680.	3.5	42
87	Pharmacological evaluation of a novel series of urea, thiourea and guanidine derivatives as P2X 7 receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2439-2442.	2.2	11
88	Rapid access to N-(indol-2-yl)amides and N-(indol-3-yl)amides as unexplored pharmacophores. Organic and Biomolecular Chemistry, 2017, 15, 576-580.	2.8	7
89	A patent review of oxytocin receptor antagonists 2013-2017. Expert Opinion on Therapeutic Patents, 2017, 27, 1287-1290.	5.0	3
90	Pharmacological Evaluation of Novel Bioisosteres of an Adamantanyl Benzamide P2X ₇ Receptor Antagonist. ACS Chemical Neuroscience, 2017, 8, 2374-2380.	3.5	30

#	ARTICLE	IF	CITATIONS
91	Pharmacology of Cumyl-Carboxamide Synthetic Cannabinoid New Psychoactive Substances (NPS) CUMYL-BICA, CUMYL-PICA, CUMYL-5F-PICA, CUMYL-5F-PINACA, and Their Analogues. ACS Chemical Neuroscience, 2017, 8, 2159-2167.	3.5	53
92	Efficient radiosynthesis of a [18F]-phosphonium salt containing closo-carborane. Tetrahedron Letters, 2017, 58, 4367-4371.	1.4	0
93	Derivatives of the pyrazolo[1,5- a]pyrimidine acetamide DPA-713 as translocator protein (TSPO) ligands and pro-apoptotic agents in human glioblastoma. European Journal of Pharmaceutical Sciences, 2017, 96, 186-192.	4.0	12
94	Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination. MedChemComm, 2017, 8, 202-210.	3.4	12
95	Comparative Evaluation of Three TSPO PET Radiotracers in a LPS-Induced Model of Mild Neuroinflammation in Rats. Molecular Imaging and Biology, 2017, 19, 77-89.	2.6	58
96	Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [¹¹ C]DPA-713 positron emission tomography. Lupus, 2017, 26, 170-178.	1.6	25
97	117.2 Translational Evaluation of Translocator Protein (TSPO) as a Marker of Neuroinflammation in Schizophrenia. Schizophrenia Bulletin, 2017, 43, S64-S64.	4.3	1
98	Detection of Neuroinflammation in a Rat Model of Subarachnoid Hemorrhage Using [18F]DPA-714 PET Imaging. Molecular Imaging, 2016, 15, 153601211663918.	1.4	15
99	In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [11C]DPA-713 PET and analysis of CSF and plasma. Translational Psychiatry, 2016, 6, e777-e777.	4.8	134
100	The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities. Forensic Toxicology, 2016, 34, 286-303.	2.4	35
101	The Formation of Seven-Membered Heterocycles under Mild Pictet-Spengler Conditions: A Route to Pyrazolo[3,4]benzodiazepines. Journal of Organic Chemistry, 2016, 81, 4883-4889.	3.2	14
102	A systematic exploration of the effects of flexibility and basicity on sigma (1f) receptor binding in a series of substituted diamines. Organic and Biomolecular Chemistry, 2016, 14, 9388-9405.	2.8	2
103	Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of frontotemporal dementia. Neuroscience Letters, 2016, 631, 24-29.	2.1	34
104	Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. ACS Chemical Neuroscience, 2016, 7, 1241-1254.	3.5	214
105	MDMA (Ecstasy™), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors. Pharmacology Biochemistry and Behavior, 2016, 150-151, 115-123.	2.9	13
106	SAT0558...New Generation Translocator Protein Pet Tracers To Image Arthritis by Macrophage Targeting in Rheumatoid Arthritis Patients: A Proof of Concept Study:. Annals of the Rheumatic Diseases, 2016, 75, 871.2-871.	0.9	0
107	Radiopharmaceuticals for PET imaging of neuroinflammation. Medecine Nucleaire, 2016, 40, 72-81.	0.2	5
108	Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1 a receptors. European Journal of Medicinal Chemistry, 2016, 108, 730-740.	5.5	11

#	ARTICLE	IF	CITATIONS
109	The Recent Development of ± 7 Nicotinic Acetylcholine Receptor (nAChR) Ligands as Therapeutic Candidates for the Treatment of Central Nervous System (CNS) Diseases. Current Pharmaceutical Design, 2016, 22, 2134-2151.	1.9	9
110	Synthesis of 7- ϵ^2 -Linked-bis-Indoles via 7-Tryptamines. Heterocycles, 2016, 93, 333.	0.7	4
111	TSPO as a target for glioblastoma therapeutics. Biochemical Society Transactions, 2015, 43, 531-536.	3.4	24
112	Lack of neuroinflammation in the HIV-1 transgenic rat: an [18F]-DPA714 PET imaging study. Journal of Neuroinflammation, 2015, 12, 171.	7.2	21
113	Structure-activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. Forensic Toxicology, 2015, 33, 355-366.	2.4	26
114	Carborane-Containing Hydroxyamidine Scaffolds as Novel Inhibitors of Indoleamine 2,3-Dioxygenase 1 (IDO1). Australian Journal of Chemistry, 2015, 68, 1866.	0.9	4
115	Amyloid load and translocator protein 18 kDa in APPswePS1-dE9 mice: a longitudinal study. Neurobiology of Aging, 2015, 36, 1639-1652.	3.1	43
116	Recent Advances in the Development of Sigma-1 Receptor Ligands. Australian Journal of Chemistry, 2015, 68, 600.	0.9	7
117	Ether analogues of DPA-714 with subnanomolar affinity for the translocator protein (TSPO). European Journal of Medicinal Chemistry, 2015, 93, 392-400.	5.5	14
118	Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 2015, 6, 1546-1559.	3.5	202
119	Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience, 2015, 6, 1445-1458.	3.5	167
120	Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. European Journal of Medicinal Chemistry, 2015, 95, 29-34.	5.5	31
121	WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action. Psychopharmacology, 2015, 232, 2659-2667.	3.1	19
122	DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications. , 2015, 151, 87-98.		122
123	Structure-activity relationship studies of SEN12333 analogues: Determination of the optimal requirements for binding affinities at ± 7 nAChRs through incorporation of known structural motifs. European Journal of Medicinal Chemistry, 2015, 95, 277-301.	5.5	12
124	Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling. Biochemical Pharmacology, 2015, 98, 587-601.	4.4	15
125	First Demonstration of Positive Allosteric-like Modulation at the Human Wild Type Translocator Protein (TSPO). Journal of Medicinal Chemistry, 2015, 58, 8743-8749.	6.4	12
126	The Therapeutic Potential of ± 7 Nicotinic Acetylcholine Receptor (± 7 nAChR) Agonists for the Treatment of the Cognitive Deficits Associated with Schizophrenia. CNS Drugs, 2015, 29, 529-542.	5.9	58

#	ARTICLE	IF	CITATIONS
127	Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study. <i>Neurobiology of Disease</i> , 2015, 74, 58-65.	4.4	208
128	Bioisosteric Fluorine in the Clandestine Design of Synthetic Cannabinoids. <i>Australian Journal of Chemistry</i> , 2015, 68, 4.	0.9	27
129	The translocator protein as a drug target in Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 439-448.	2.8	20
130	Structure-activity relationships of N-substituted 4-(trifluoromethoxy)benzamidines with affinity for GluN2B-containing NMDA receptors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 828-830.	2.2	17
131	Regional brain distribution of translocator protein using [11C]DPA-713 PET in individuals infected with HIV. <i>Journal of NeuroVirology</i> , 2014, 20, 219-232.	2.1	78
132	Altered proteostasis in aging and heat shock response in <i>C. elegans</i> revealed by analysis of the global and de novo synthesized proteome. <i>Cellular and Molecular Life Sciences</i> , 2014, 71, 3339-3361.	5.4	63
133	The First CNS-Active Carborane: A Novel P2X ₇ Receptor Antagonist with Antidepressant Activity. <i>ACS Chemical Neuroscience</i> , 2014, 5, 335-339.	3.5	118
134	Body temperature and cardiac changes induced by peripherally administered oxytocin, vasopressin and the non-peptide oxytocin receptor agonist WAY-267,464: a biotelemetry study in rats. <i>British Journal of Pharmacology</i> , 2014, 171, 2868-2887.	5.4	70
135	[¹⁸ F]DPA-C5yne, a novel fluorine-18 labelled analogue of DPA-714: radiosynthesis and preliminary evaluation as a radiotracer for imaging neuroinflammation with PET. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2014, 57, 410-418.	1.0	11
136	Bio-orthogonal labeling as a tool to visualize and identify newly synthesized proteins in <i>Caenorhabditis elegans</i> . <i>Nature Protocols</i> , 2014, 9, 2237-2255.	12.0	39
137	Pyrazolo[1,4]diazepines as non-peptidic probes of the oxytocin and vasopressin receptors. <i>Tetrahedron Letters</i> , 2014, 55, 4568-4571.	1.4	8
138	Investigations of amide bond variation and biaryl modification in analogues of ± 7 nAChR agonist SEN12333. <i>European Journal of Medicinal Chemistry</i> , 2014, 84, 200-205.	5.5	2
139	Promising potential of new generation translocator protein tracers providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritis. <i>Arthritis Research and Therapy</i> , 2014, 16, R70.	3.5	32
140	Could ¹⁸ F-DPA-714 PET imaging be interesting to use in the early post-stroke period?. <i>EJNMMI Research</i> , 2014, 4, 28.	2.5	40
141	Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: Amelioration by COX-2 inhibition. <i>Brain, Behavior, and Immunity</i> , 2014, 41, 173-181.	4.1	35
142	P2X7 in Bipolar and Depressive Disorders. , 2014, , 635-661.		2
143	The Fifth Element in Drug Design: Boron in Medicinal Chemistry. <i>Australian Journal of Chemistry</i> , 2013, 66, 1118.	0.9	48
144	A practical synthesis of (1S,4S)-2,5-diazabicyclo[2.2.1]heptane. <i>Tetrahedron Letters</i> , 2013, 54, 5345-5347.	1.4	9

#	ARTICLE	IF	CITATIONS
145	The development of CNS-active LRRK2 inhibitors using property-directed optimisation. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2013, 23, 3690-3696.	2.2	24
146	Improved accessibility to the desoxy analogues of Δ^9 -tetrahydrocannabinol and cannabidiol. <i>Tetrahedron Letters</i> , 2013, 54, 52-54.	1.4	22
147	Acute Prosocial Effects of Oxytocin and Vasopressin When Given Alone or in Combination with 3,4-Methylenedioxymethamphetamine in Rats: Involvement of the V1A Receptor. <i>Neuropsychopharmacology</i> , 2013, 38, 2249-2259.	5.4	112
148	N-substituted 8-aminopentacyclo[5.4.0.0 ^{2,6} .0 ^{3,10} .0 ^{5,9}]undecanes as μ receptor ligands with potential neuroprotective effects. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 6038-6052.	3.0	16
149	The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse. <i>ACS Chemical Neuroscience</i> , 2013, 4, 1081-1092.	3.5	80
150	The translocator protein (TSPO): A novel target for cancer chemotherapy. <i>International Journal of Biochemistry and Cell Biology</i> , 2013, 45, 1212-1216.	2.8	82
151	Synthesis of Biologically Active Seven-Membered-Ring Heterocycles. <i>Synthesis</i> , 2013, 45, 3211-3227.	2.3	30
152	Metabolism and Quantification of [¹⁸ F]DPA-714, a New TSPO Positron Emission Tomography Radioligand. <i>Drug Metabolism and Disposition</i> , 2013, 41, 122-131.	3.3	61
153	The development of radiotracers for imaging sigma (σ) receptors in the central nervous system (CNS) using positron emission tomography (PET). <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2013, 56, 215-224.	1.0	11
154	OP0235...Pet high affinity translocator protein ligands as a novel modality for macrophage targeting in arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 135.2-135.	0.9	0
155	[¹⁸ F]DPA-714: Direct Comparison with [¹¹ C]PK11195 in a Model of Cerebral Ischemia in Rats. <i>PLoS ONE</i> , 2013, 8, e56441.	2.5	77
156	Radiation Dosimetry and Biodistribution of the TSPO Ligand 11C-DPA-713 in Humans. <i>Journal of Nuclear Medicine</i> , 2012, 53, 330-335.	5.0	23
157	Is there Any Correlation Between Binding and Functional Effects at the Translocator Protein (TSPO) (18 kDa)?. <i>Current Molecular Medicine</i> , 2012, 12, 387-397.	1.3	0
158	Evidence for Complex Binding Profiles and Species Differences at the Translocator Protein (TSPO) (18 kDa). <i>Journal of Molecular Biology</i> , 2012, 421, 1-18.	1.3	18
159	The Therapeutic Potential of Sigma (σ) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence. <i>Current Pharmaceutical Design</i> , 2012, 18, 884-901.	1.9	39
160	7-Azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (σ_2) receptor ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2012, 22, 4059-4063.	2.2	11
161	Effects of Translocator Protein (18 kDa) Ligands on Microglial Activation and Neuronal Death in the Quinolinic-Acid-Injected Rat Striatum. <i>ACS Chemical Neuroscience</i> , 2012, 3, 114-119.	3.5	43
162	Initial evaluation in healthy humans of [¹⁸ F]DPA-714, a potential PET biomarker for neuroinflammation. <i>Nuclear Medicine and Biology</i> , 2012, 39, 570-578.	0.6	115

#	ARTICLE	IF	CITATIONS
163	Exploration of ring size in a series of cyclic vicinal diamines with α_1 receptor affinity. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 5493-5497.	2.2	11
164	Inhibition of human recombinant α_1 type calcium channels by α -arachidonoyl 5-HT. British Journal of Pharmacology, 2012, 167, 1076-1088.	5.4	18
165	A α_1 receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecan-3-ols (AHDs). Bioorganic and Medicinal Chemistry Letters, 2012, 22, 6053-6058.	2.2	15
166	Molecular Imaging of Microglial Activation in Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e52941.	2.5	203
167	Synthesis and Biological Evaluation of Adenosines with Heterobicyclic and Polycyclic α_1 Substituents as Adenosine α_1 Receptor Agonists. ChemMedChem, 2012, 7, 1191-1201.	3.2	5
168	Consequences of linker length alteration of the α_7 nicotinic acetylcholine receptor (nAChR) agonist, SEN12333. Bioorganic and Medicinal Chemistry Letters, 2012, 22, 2380-2384.	2.2	7
169	The Nonpeptide Oxytocin Receptor Agonist WAY 267,464: Receptor Binding Profile, Prosocial Effects and Distribution of c-Fos Expression in Adolescent Rats. Journal of Neuroendocrinology, 2012, 24, 1012-1029.	2.6	63
170	A practical, multigram synthesis of the 2-(2-(4-alkoxyphenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide (DPA) class of high affinity translocator protein (TSPO) ligands. Tetrahedron Letters, 2012, 53, 3780-3783.	1.4	11
171	Is there Any Correlation Between Binding and Functional Effects at the Translocator Protein (TSPO) (18 kDa)? Current Molecular Medicine, 2012, 12, 387-397.	1.3	24
172	Evidence for Complex Binding Profiles and Species Differences at the Translocator Protein (TSPO) (18 kDa). Journal of Neuroendocrinology, 2012, 24, 1012-1029.	1.3	17
173	Synthesis and cellular uptake of boron-rich pyrazolopyrimidines: exploitation of the translocator protein for the efficient delivery of boron into human glioma cells. Chemical Communications, 2011, 47, 12179.	4.1	31
174	Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain, Behavior, and Immunity, 2011, 25, 1113-1122.	4.1	173
175	Boron in Drug Discovery: Carboranes as Unique Pharmacophores in Biologically Active Compounds. Chemical Reviews, 2011, 111, 5701-5722.	47.7	595
176	Resilience and reduced c-Fos expression in P2X7 receptor knockout mice exposed to repeated forced swim test. Neuroscience, 2011, 189, 170-177.	2.3	95
177	Synthesis of 6-[18 F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 4819-4822.	2.2	28
178	N-Arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (α) receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5289-5292.	2.2	21
179	Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N-(methoxyphenylalkyl)piperazine α_1 receptor ligands. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 5707-5710.	2.2	7
180	Synthesis and in vivo evaluation of [18 F]N-(2-benzofuranylmethyl)-N-(4-(2-fluoroethoxy)benzyl)piperazine, a novel α_1 receptor PET imaging agent. Bioorganic and Medicinal Chemistry Letters, 2011, 21, 6820-6823.	2.2	11

#	ARTICLE	IF	CITATIONS
181	Reduced PBR/TSPO Expression After Minocycline Treatment in a Rat Model of Focal Cerebral Ischemia: A PET Study Using [18F]DPA-714. <i>Molecular Imaging and Biology</i> , 2011, 13, 10-15.	2.6	63
182	Trishomocubane as a scaffold for the development of selective dopamine transporter (DAT) ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 38-41.	2.2	17
183	Molecular hybridization of 4-azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecane-3-ol with sigma (σ) receptor ligands modulates off-target activity and subtype selectivity. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3622-3626.	2.2	13
184	The Translocator Protein. <i>Journal of Nuclear Medicine</i> , 2011, 52, 677-680.	5.0	139
185	Boronated phosphonium salts containing arylboronic acid, closo-carborane, or nido-carborane: synthesis, X-ray diffraction, in vitro cytotoxicity, and cellular uptake. <i>Journal of Biological Inorganic Chemistry</i> , 2010, 15, 1305-1318.	2.6	21
186	The development of PET radioligands for imaging the translocator protein (18 kDa): What have we learned?. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2010, 53, 501-510.	1.0	11
187	Oxo-bridged isomers of aza-trishomocubane sigma (σ) receptor ligands: Synthesis, in vitro binding, and molecular modeling. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 145-148.	2.2	27
188	Pyrazolo[1,5-a]pyrimidine acetamides: 4-Phenyl alkyl ether derivatives as potent ligands for the 18 kDa translocator protein (TSPO). <i>Bioorganic and Medicinal Chemistry Letters</i> , 2010, 20, 5799-5802.	2.2	35
189	Evaluation of the PBR/TSPO Radioligand [¹⁸ F]DPA-714 in a Rat Model of Focal Cerebral Ischemia. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 230-241.	4.3	184
190	11-[[2-(3-Fluorophenyl)ethyl](methyl)amino]pentacyclo[5.4.0.02,6.03,10.05,9]undecan-8-one. <i>Acta Crystallographica Section E: Structure Reports Online</i> , 2010, 66, o2693-o2693.	0.2	1
191	PET Radioligands for the Vesicular Acetylcholine Transporter (VACHT). <i>Current Topics in Medicinal Chemistry</i> , 2010, 10, 1569-1583.	2.1	54
192	Insights into Structure-Activity Relationships and CNS Therapeutic Applications of NR2B Selective Antagonists. <i>Current Medicinal Chemistry</i> , 2010, 17, 4166-4190.	2.4	23
193	Development of Vesicular Acetylcholine Transporter Ligands: Molecular Probes for Alzheimers Disease. <i>Current Bioactive Compounds</i> , 2010, 6, 129-155.	0.5	5
194	Design, Synthesis, and Structure-Affinity Relationships of Regioisomeric N-Benzyl Alkyl Ether Piperazine Derivatives as σ -1 Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 6228-6239.	6.4	62
195	P2X purinergic receptor ligands: recently patented compounds. <i>Expert Opinion on Therapeutic Patents</i> , 2010, 20, 625-646.	5.0	77
196	Attenuation correction for the large non-human primate brain imaging using microPET. <i>Physics in Medicine and Biology</i> , 2010, 55, 2351-2363.	3.0	2
197	Fluorine-18 Chemistry for PET: A Concise Introduction. <i>Current Radiopharmaceuticals</i> , 2010, 3, 68-80.	0.8	36
198	Editorial [Hot topic: (Part I) Focus on [18F]fluoride Radiochemistry (Guest Editors: D. Roeda, M.) <i>Tj ETQq0 0 0 rgBT/Q Overlock 10 Tf 50 6</i>	0.8	0

#	ARTICLE	IF	CITATIONS
199	Extracellular Loops 2 and 4 of GLYT2 Are Required for N-Arachidonylglycine Inhibition of Glycine Transport. <i>Journal of Biological Chemistry</i> , 2009, 284, 36424-36430.	3.4	27
200	Initial Evaluation of ¹¹ C-DPA-713, a Novel TSPO PET Ligand, in Humans. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1276-1282.	5.0	117
201	Recent Advances in the Mitsunobu Reaction: Modifications and Applications to Biologically Active Molecules. <i>Current Organic Chemistry</i> , 2009, 13, 1610-1632.	1.6	44
202	Radiolabelled Molecules for Imaging the Translocator Protein (18 kDa) Using Positron Emission Tomography. <i>Current Medicinal Chemistry</i> , 2009, 16, 2899-2923.	2.4	123
203	Comparative Evaluation of the Translocator Protein Radioligands ¹¹ C-DPA-713, ¹⁸ F-DPA-714, and ¹¹ C-PK11195 in a Rat Model of Acute Neuroinflammation. <i>Journal of Nuclear Medicine</i> , 2009, 50, 468-476.	5.0	208
204	18F-ZW-104: A New Radioligand for Imaging Neuronal Nicotinic Acetylcholine Receptorsâ€”In Vitro Binding Properties and PET Studies in Baboons. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1349-1355.	5.0	18
205	[11C]-DPA-713 and [18F]-DPA-714 as New PET Tracers for TSPO: A Comparison with [11C]-(R)-PK11195 in a Rat Model of Herpes Encephalitis. <i>Molecular Imaging and Biology</i> , 2009, 11, 386-98.	2.6	113
206	Water-soluble phosphonium salts containing 1,12-dicarba-closo-dodecaborane(12). <i>Tetrahedron Letters</i> , 2009, 50, 6457-6461.	1.4	13
207	Purinergic P2X7 receptor antagonists: Chemistry and fundamentals of biological screening. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 4861-4865.	3.0	10
208	The Translocator Protein (18 kDa): Central Nervous System Disease and Drug Design. <i>Journal of Medicinal Chemistry</i> , 2009, 52, 581-592.	6.4	92
209	Challenges in molecular imaging of Parkinsonâ€™s disease: A brief overview. <i>Brain Research Bulletin</i> , 2009, 78, 105-108.	3.0	7
210	Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model. <i>Brain Research Bulletin</i> , 2009, 78, 85-90.	3.0	17
211	Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+parafascicular lesions. <i>Brain Research Bulletin</i> , 2009, 78, 91-96.	3.0	12
212	Oral pre-treatment with epigallocatechin gallate in 6-OHDA lesioned rats produces subtle symptomatic relief but not neuroprotection. <i>Brain Research Bulletin</i> , 2009, 80, 397-402.	3.0	22
213	Dopamine D1 Receptor Imaging in the Rodent and Primate Brain Using the Isoquinoline (+)-[11C]A-69024 and Positron Emission Tomography. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 2811-2819.	3.3	6
214	Radiosynthesis of [¹⁸ F]DPA-714, a selective radioligand for imaging the translocator protein (18 kDa) with PET. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2008, 51, 286-292.	1.0	76
215	Cubyl amides: Novel P2X7 receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 3720-3723.	2.2	34
216	NEUROPROTECTIVE EFFECTS OF A SELECTIVE N-METHYL- α -ASPARTATE NR2B RECEPTOR ANTAGONIST IN THE 6-HYDROXYDOPAMINE RAT MODEL OF PARKINSON'S DISEASE. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2008, 35, 1388-1394.	1.9	21

#	ARTICLE	IF	CITATIONS
217	Synthesis and In-Vivo Evaluation of [11C]p-PVP-MEMA as a PET Radioligand for Imaging Nicotinic Receptors. Australian Journal of Chemistry, 2008, 61, 438.	0.9	5
218	Behavioural effects of trishomocubanes in rats with unilateral 6-hydroxydopamine lesions. Behavioural Brain Research, 2008, 190, 14-21.	2.2	15
219	DPA-714, a New Translocator Proteinâ€“Specific Ligand: Synthesis, Radiofluorination, and Pharmacologic Characterization. Journal of Nuclear Medicine, 2008, 49, 814-822.	5.0	237
220	11C-DPA-713: A Novel Peripheral Benzodiazepine Receptor PET Ligand for In Vivo Imaging of Neuroinflammation. Journal of Nuclear Medicine, 2007, 48, 573-581.	5.0	137
221	Imaging Sigma Receptors: Applications in Drug Development. Current Pharmaceutical Design, 2007, 13, 51-72.	1.9	78
222	Molecular Probes for P2X7 Receptor Studies. Current Medicinal Chemistry, 2007, 14, 1505-1523.	2.4	42
223	Editorial [Hot Topic: Molecular Imaging in Drug Development (Executive Editor: M. Kassiou)]. Current Pharmaceutical Design, 2007, 13, 1-1.	1.9	8
224	High-resolution imaging of the large non-human primate brain using microPET: a feasibility study. Physics in Medicine and Biology, 2007, 52, 6627-6638.	3.0	7
225	(E)-[125I]-5-AOIBV: a SPECT radioligand for the vesicular acetylcholine transporter. Nuclear Medicine and Biology, 2007, 34, 967-971.	0.6	5
226	Decreased vesicular acetylcholine transporter and $\alpha 4 \beta 2$ nicotinic receptor density in the rat brain following 192 IgG-saporin immunolesioning. Neuroscience Letters, 2007, 415, 97-101.	2.1	10
227	Acetylenic Pyridines for Use in PET Imaging of Nicotinic Receptors. ChemMedChem, 2007, 2, 54-57.	3.2	11
228	Positron Emission Tomography Imaging of Neuroinflammation. Neurotherapeutics, 2007, 4, 443-452.	4.4	119
229	(1R,2S,3R,6S,7R,8S)-Tricyclo[6.2.1.0 ^{2,7}]undeca-4,9-diene-3,6-diol. Acta Crystallographica Section E: Structure Reports Online, 2007, 63, o92-o93.	0.2	0
230	Ex vivo and in vivo evaluation of (2 <i>R</i> ,3 <i>R</i>)-5- ¹⁸ F-fluoroethoxy- and fluoropropoxy- α -benzovesamicol, as PET radioligands for the vesicular acetylcholine transporter. Synapse, 2007, 61, 962-970.	1.2	21
231	Trishomocubanes: Novel $\alpha 7$ ligands modulate cocaine-induced behavioural effects. European Journal of Pharmacology, 2007, 555, 37-42.	3.5	25
232	Developing a preclinical model of Parkinson's disease: A study of behaviour in rats with graded 6-OHDA lesions. Behavioural Brain Research, 2006, 169, 1-9.	2.2	109
233	Synthesis and Radiolabelling of Ipratropium and Tiotropium for Use as PET Ligands in the Study of Inhaled Drug Deposition. Australian Journal of Chemistry, 2006, 59, 53.	0.9	7
234	In vivo evidence for microglial activation in neurodegenerative dementia. Acta Neurologica Scandinavica, 2006, 114, 107-114.	2.1	61

#	ARTICLE	IF	CITATIONS
235	Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 1297-1300.	2.2	12
236	Synthesis and in vitro evaluation of N-substituted aza-trozamicol analogs as vesicular acetylcholine transporter ligands. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2006, 16, 2654-2657.	2.2	6
237	Radiosynthesis of (E)-N-(2-[¹¹ C]methoxybenzyl)-3-phenyl-acrylamidine, a novel subnanomolar NR2B subtype-selective NMDA receptor antagonist. <i>Applied Radiation and Isotopes</i> , 2006, 64, 348-354.	1.5	13
238	Improved synthesis of the peripheral benzodiazepine receptor ligand [¹¹ C]DPA-713 using [¹¹ C]methyl triflate. <i>Applied Radiation and Isotopes</i> , 2006, 64, 570-573.	1.5	37
239	Development of Ligands for the Peripheral Benzodiazepine Receptor. <i>Current Medicinal Chemistry</i> , 2006, 13, 1991-2001.	2.4	83
240	Influence of Trishomocubanes on Sigma Receptor Binding of N-(1-Benzylpiperidin-) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 ₃ Td (4-yl)-4	1.5	3
241	Synthesis and in vitro evaluation of new benzovesamicol analogues as potential imaging probes for the vesicular acetylcholine transporter. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 745-753.	3.0	38
242	Synthesis and in vivo evaluation of a new PET radioligand for studying sigma-2 receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 3623-3626.	3.0	25
243	Synthesis and in vivo evaluation of a novel peripheral benzodiazepine receptor PET radioligand. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 6188-6194.	3.0	108
244	Small animal SPECT and its place in the matrix of molecular imaging technologies. <i>Physics in Medicine and Biology</i> , 2005, 50, R45-R61.	3.0	286
245	Sequential ¹²³ I-iododexetimide scans in temporal lobe epilepsy: comparison with neuroimaging scans (MR imaging and ¹⁸ F-FDG PET imaging). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005, 32, 180-185.	6.4	10
246	Editorial [Hot Topic: Capabilities of PET and SPECT in Pre-Clinical and Clinical Research (Executive) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 542 ₃ Td (4-yl)-4	1.9	0
247	Ligands for peripheral benzodiazepine binding sites in glial cells. <i>Brain Research Reviews</i> , 2005, 48, 207-210.	9.0	39
248	Development of Radioligands for In Vivo Imaging of GABAA-Benzodiazepine Receptors. <i>Mini-Reviews in Medicinal Chemistry</i> , 2004, 4, 909-921.	2.4	16
249	The role of positron emission tomography in the discovery and development of new drugs; As studied in laboratory animals. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2004, 29, 1-6.	1.6	15
250	Radiosynthesis and in vivo evaluation of [¹¹ C]Ro-647312: a novel NR1/2B subtype selective NMDA receptor radioligand. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2004, 47, 911-920.	1.0	16
251	Radiosynthesis and pharmacological evaluation of [¹¹ C]EMD-95885: a high affinity ligand for NR2B-containing NMDA receptors. <i>Bioorganic and Medicinal Chemistry</i> , 2004, 12, 3229-3237.	3.0	39
252	3-Pyridyl ethers as SPECT radioligands for imaging nicotinic acetylcholine receptors. <i>Applied Radiation and Isotopes</i> , 2004, 60, 669-676.	1.5	3

#	ARTICLE	IF	CITATIONS
253	Synthesis, radiosynthesis and In vivo evaluation of 5-[3-(4-Benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzimidazol-2-[11C]one, as a potent NR1A/2B subtype selective NMDA PET radiotracer. <i>Bioorganic and Medicinal Chemistry</i> , 2003, 11, 5401-5408.	3.0	32
254	Pharmacological evaluation of (S)-8-[123I]iodobretazenil: a radioligand for in vivo studies of central benzodiazepine receptors. <i>Nuclear Medicine and Biology</i> , 2003, 30, 191-198.	0.6	8
255	Synthesis and evaluation of iodine-123 labelled tricyclic tropanes as radioligands for the serotonin transporter. <i>Nuclear Medicine and Biology</i> , 2003, 30, 741-746.	0.6	10
256	Quantification of 5-[123 I] IODO-A-85380 in nonhuman primates using SPECT: Parameter identifiability and stability. <i>IFAC Postprint Volumes IPPV / International Federation of Automatic Control</i> , 2003, 36, 185-190.	0.4	0
257	KINETIC MODELLING OF NICOTINIC ACETYLCHOLINE RECEPTORS WITH 5-[123I] IODO-A-85380 AND DYNAMIC SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY. <i>IFAC Postprint Volumes IPPV / International Federation of Automatic Control</i> , 2002, 35, 121-126.	0.4	0
258	(+)-[76Br]A-69024: a non-benzazepine radioligand for studies of dopamine D1 receptors using PET. <i>Nuclear Medicine and Biology</i> , 2002, 29, 295-302.	0.6	12
259	Preparation of a bromine-76 labelled analogue of epibatidine: a potent ligand for nicotinic acetylcholine receptor studies. <i>Applied Radiation and Isotopes</i> , 2002, 57, 713-717.	1.5	11
260	Pharmacological evaluation of a Br-76 analog of epibatidine: A potent ligand for studying brain nicotinic acetylcholine receptors. <i>Synapse</i> , 2002, 45, 95-104.	1.2	17
261	In vivo imaging of nicotinic receptor upregulation following chronic (-)-nicotine treatment in baboon using SPECT. <i>Nuclear Medicine and Biology</i> , 2001, 28, 165-175.	0.6	59
262	Pharmacological evaluation of (+)-2-[123I]A-69024 A radioligand for in vivo studies of dopamine D1 receptors. <i>Life Sciences</i> , 2001, 69, 669-675.	4.3	3
263	Trishomocubanes: novel $\text{I}\ddot{\text{f}}$ -receptor ligands modulate amphetamine-stimulated [3H]dopamine release. <i>European Journal of Pharmacology</i> , 2001, 422, 39-45.	3.5	34
264	Trishomocubanes: Requirements for $\text{I}\ddot{\text{f}}$ Receptor Binding and Subtype Selectivity. <i>Australian Journal of Chemistry</i> , 2001, 54, 31.	0.9	15
265	Radiosynthesis of bromine-76 and iodine-123 labelled enantiomers of A-69024: radioligands for dopamine D1 receptor studies using PET and SPECT. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2000, 43, 339-346.	1.0	3
266	X-Ray Crystallographic Structures of Biologically Active Trishomocubanes of the Types Pentacyclo[5.4.0.02,6.03,10.05,9]undecylamines and 4-Azahexacyclo[5.4.1.02,6.03,10.05,9.08,11]dodecane. <i>Australian Journal of Chemistry</i> , 2000, 53, 899.	0.9	2
267	The influence of tomograph sensitivity on kinetic parameter estimation in positron emission tomography imaging studies of the rat brain. <i>Nuclear Medicine and Biology</i> , 2000, 27, 617-625.	0.6	15
268	A study of myocardial muscarinic receptors in streptozotocin-induced diabetic rats using iodine-123 N-methyl-4-iododexetimide. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1999, 26, 743-749.	6.4	0
269	In vitro and in vivo characterisation of [3H]ANSTO-14 binding to the $\text{I}\ddot{\text{f}}1$ binding sites. <i>Nuclear Medicine and Biology</i> , 1999, 26, 209-215.	0.6	7
270	Effects of streptozotocin-induced diabetes on neuronal sigma receptors in the rat brain. <i>Life Sciences</i> , 1999, 65, PL281-PL286.	4.3	8

#	ARTICLE	IF	CITATIONS
271	Synthesis and Binding Studies of Trishomocubanes: Novel Ligands for 5-HT_{1A} Binding Sites. Australian Journal of Chemistry, 1999, 52, 653.	0.9	12
272	5-HT_{1A} -Binding site ligands inhibit K^+ currents in rat locus coeruleus neurons in vitro. European Journal of Pharmacology, 1998, 361, 157-163.	3.5	14
273	Pharmacological evaluation of [^{11}C]A-84543: An enantioselective ligand for in vivo studies of neuronal nicotinic acetylcholine receptors. Life Sciences, 1998, 63, PL13-PL18.	4.3	28
274	Synthesis and evaluation of halogenated dibenzodiazepines as muscarinic receptor ligands. Bioorganic and Medicinal Chemistry Letters, 1997, 7, 799-804.	2.2	5
275	Synthesis of 3-[(1-[^{11}C]methyl-2(S)-pyrrolidinyl) methoxy]pyridine and 3-[(1-[^{11}C]methyl-2(R)-pyrrolidinyl) methoxy]pyridine: Radioligands for in vivo studies of neuronal nicotinic acetylcholine receptors. Journal of Labelled Compounds and Radiopharmaceuticals, 1997, 39, 425-431.	1.0	10
276	Radiosynthesis of [^{123}I]N-methyl-4-iododexetimide and [^{123}I]N-methyl-4-iodolevetimide: In vitro and in vivo characterisation of binding to muscarinic receptors in the rat heart. Nuclear Medicine and Biology, 1996, 23, 147-153.	0.6	9
277	Pharmacological characterization and positron emission tomography evaluation of 4-[^{76}Br]bromodexetimide and 4-[^{76}Br]bromolevetimide for investigations of central muscarinic cholinergic receptors. Nuclear Medicine and Biology, 1996, 23, 235-243.	0.6	4
278	In vitro pharmacological properties of 4-bromodexetimide for muscarinic receptors. Life Sciences, 1996, 58, PL337-PL344.	4.3	2
279	Comparison of binding parameters of 5-HT_{1A} and 5-HT_{1B} binding sites in rat and guinea pig brain membranes: novel subtype-selective trishomocubanes. European Journal of Pharmacology, 1996, 311, 233-240.	3.5	44
280	Synthesis of iodine-123 labelled analogues of the partial agonist (S)- and (R)-bretazenil for the study of CNS benzodiazepine receptors using SPECT. Journal of Labelled Compounds and Radiopharmaceuticals, 1996, 38, 835-845.	1.0	4
281	Synthesis of iodine-123 labelled analogues of imidazenil and ethyl-imidazenil for studying benzodiazepine receptors using SPECT. Journal of Labelled Compounds and Radiopharmaceuticals, 1996, 38, 1121-1132.	1.0	3
282	Trishomocubanes, a new class of selective and high affinity ligands for the sigma binding site. Bioorganic and Medicinal Chemistry Letters, 1996, 6, 595-600.	2.2	23
283	Localization of temporal lobe epileptic foci with iodine-123 iododexetimide cholinergic neuroreceptor single-photon emission computed tomography. Neurology, 1996, 47, 1015-1020.	1.1	18
284	Synthesis of [^{76}Br]4-bromodexetimide and [^{76}Br]4-bromolevetimide: Radiotracers for studying muscarinic cholinergic receptors using PET. Journal of Labelled Compounds and Radiopharmaceuticals, 1995, 36, 259-266.	1.0	8
285	Iodine-123N- methyl-4-iododexetimide: a new radioligand for single-photon emission tomographic imaging of myocardial muscarinic receptors. European Journal of Nuclear Medicine and Molecular Imaging, 1995, 22, 339-345.	2.1	9
286	[^{11}C]A-69024: A potent and selective non-benzazepine radiotracer for in vivo studies of dopamine D1 receptors. Nuclear Medicine and Biology, 1995, 22, 221-226.	0.6	14
287	[^3H]A-69024: A non-benzazepine ligand for in vitro and in vivo studies of dopamine d1 receptors. Life Sciences, 1995, 57, PL367-PL372.	4.3	2
288	Human dosimetry and biodistribution of iodine-123-iododexetimide: a SPECT imaging agent for cholinergic muscarinic neuroreceptors. Journal of Nuclear Medicine, 1995, 36, 1332-8.	5.0	14

#	ARTICLE	IF	CITATIONS
289	Synthesis and stereochemical assignment of 2,5-trans-2,5-dimethylperhydro-2,2'-bipyrimidine and heterocycles derived from its condensation with formaldehyde. Tetrahedron, 1994, 50, 2497-2506.	1.9	2
290	Radiosynthesis of (±)-1-(2-bromo-4,5-dimethoxybenzyl)-7-hydroxy-6-methoxy-2-[11C]-methyl-1,2,3,4-tetrahydro-isoquinoline, [11C]A-69024: A non-benzazepine antagonist for studying dopamine D1 receptors In vivo using PET. Journal of Labelled Compounds and Radiopharmaceuticals, 1994, 34, 431-437.	1.0	9
291	Reactions of perhydro-2,2'-bipyrimidines with carbonyl compounds bearing .alpha.-carbonyl functionality. Journal of Organic Chemistry, 1993, 58, 5753-5758.	3.2	6
292	Synthesis and stereochemical assignment of heterocycles derived from (2S*,2'S*,4R*,4'R*,6S*,6'S*)-4,4',6,6'-tetramethylperhydro-2,2'-bipyrimidine. Journal of Organic Chemistry, 1992, 57, 3901-3905.	3.2	8
293	Unexpected formation of 5,12-dimethyl-3,7,10,14,15,16-tetraazapentacyclo[7.5.1.12,8.15,16.112,15]octadecane, a novel caged nitrogen heterocycle, and preparation and X-ray crystal structure of its copper(II)chloride complex. Journal of the Chemical Society Chemical Communications, 1991, , 607.	2.0	4
294	Evidence for equatorial bridging in 2,2'-bis(hexahydropyrimidines), perhydro-4,5,8a,9a-tetraazafluorenes, and perhydro-3a,4a,7a,8a-tetraazacyclopentanofluorenes through one-bond carbon-hydrogen coupling. Journal of Organic Chemistry, 1991, 56, 4308-4312.	3.2	6
295	Preferred Equatorial Linkages of Hexahydropyrimidine Rings in Dodecahydro-2,2'-bipyrimidines. Australian Journal of Chemistry, 1991, 44, 143.	0.9	6